BioRestorative Therapies (BRTX) Cash from Operations (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Cash from Operations came in at 2400000.0 in Q4 2025, down 2.22% YoY from 2454524.78 in Q4 2024, and up 17.24% on a QoQ basis from 2900000.0 in Q3 2025.
BioRestorative Therapies (BRTX) Cash from Operations (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Cash from Operations data on file, last reported at 2400000.0 in Q4 2025.
- Quarterly Cash from Operations fell 2.22% year-over-year to 2400000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10800000.0 (down 31.22% YoY) and the FY2025 annual result came in at 10800000.0, down 31.22% from the prior year.
- Cash from Operations climbed to 2400000.0 in Q4 2025, from 2900000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 629364.0 in Q3 2021 to a low of 2900000.0 in Q3 2025.
- A 5-year average of 1735178.25 and a median of 1605161.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 130.65% — and 2023, when it advanced 18.75%.
- Tracing BRTX's Cash from Operations over 5 years: stood at 1145014.0 in 2021, then plunged by 41.11% to 1615688.0 in 2022, then increased by 1.72% to 1587962.0 in 2023, then slumped by 47.85% to 2347845.0 in 2024, then declined by 2.22% to 2400000.0 in 2025.
- The last three Cash from Operations figures came in at 2400000.0 (Q4 2025), 2900000.0 (Q3 2025), and 2721214.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | -2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.40 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Sep 30, 2025 | -2.90 Mn |
| Sep 30, 2025 | -2.90 Mn |
| Jun 30, 2025 | -2.72 Mn |
| Jun 30, 2025 | -2.72 Mn |
| Mar 31, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.78 Mn |
| Dec 31, 2024 | -2.35 Mn |
| Dec 31, 2024 | -2.35 Mn |
| Sep 30, 2024 | -1.70 Mn |
| Sep 30, 2024 | -1.70 Mn |
| Jun 30, 2024 | -1.87 Mn |
| Jun 30, 2024 | -1.87 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.18 Mn |
| Sep 30, 2023 | -1.18 Mn |